Reflecting on my ACRS trading journey. Lessons from swing strategies, risk management, and market catalysts. A personal record of growth and discipline in navigating Aclaris Therapeutics stock.
Why ACRS
Aclaris Therapeutics (ACRS) popped up on the NDU’s Live Alerts in late April 2026. Financially, the company is not profitable and revenue is declining. I usually do not invest or trade in companies that are not profitable. But market sentiment seems upbeat and I have been trying to learn how to do some speculative trading using the NDU system and ACRS looks like a good candidate which does not require a lot of capital.
ACRS is a clinical-stage biotech developing novel immuno-inflammatory therapies, primarily targeting unmet needs in dermatology and respiratory health. It was incorporated in 2012 and publicly listed in 2015.
- Current price: $4.40
- Market cap: US$615.9 million
- 52-week trading range: $1.16 – $4.89
- Historical range: $0.590 – $33.88
- No dividend and no moat
Positive Elements
Management seems to be competent. They have made progress to reduce net loss, maintains cashflow, and raised $20 million in equity financing in early 2026 to strengthen its balance sheet and advance research.
Key clinical readouts for ATI-052 and ATI-2138 is expected in late 2026, which may serve as major potential catalysts.
Analyst consensus is positive. The average 12-month price target is $11.50, with a high of $16.00 and a low of $10.00, implying substantial upside from the current price.
Stock price is performing much better than other same sector stocks.
Price trend is on an uptrend with mostly small candles and multiple pullbacks (blue arrows). Turned blue in early March. It is respecting the 50MA and trading in the upper half of the Bollinger band.
In short, the stock has performed strongly off its lows, and analyst sentiment is very bullish with price targets significantly above the current level.
Financial snapshot: https://www.tradingview.com/symbols/NASDAQ-ACRS/financials-overview/?ratios-period=FY&revenue_water_fall-period=FY&income+statements-period=FY
ACRS Trading Plan
I did not choose options trading because there are no weekly options as volume is low. The price is also below $10 so capital for stock purchase is not onerous.
Swing trading seems the more appropriate strategy. Commissions on stock trading is also lower than options trading on Moomoo.
- Capital: $1,000. My capital is small because it is what I am comfortable with.
- Risk: $400. I am willing to lose up to half of my capital.
- Take Profit: At first red arrow in the NDU system
- Add shares if next blue arrow appear
My Trades
| Dates | Notes (Entry & Exit) | Cost/Profit | ROI |
|---|---|---|---|
| Open: 30 Apr 2026 | Purchase 200 shares at $4.40 each | Cost: $881.73 | |
Let the experiment begins!
Disclaimer: This post is a personal account of my investing and trading journey. I’m not a financial adviser. Please perform your due diligence before investing.
Leave a comment